A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
NCT ID: NCT06977880
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
80 participants
INTERVENTIONAL
2025-02-19
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY2969822 in Healthy Participants
NCT02018887
A Study of LY2775240 in Healthy Participants
NCT02963779
A Study of LY2886721 in Healthy Participants
NCT01534273
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
NCT06912295
A Study of LY4005130 in Healthy Participants
NCT06690996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A1
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort A2
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort A3
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort A4
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort A5
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort A6 (Optional)
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort B1
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort B2
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort B3
Participants received LY4292009 orally.
LY4292009
Administered orally
Cohort B4 (Optional)
Participants received LY4292009 orally.
LY4292009
Administered orally
Placebo
Participants receive placebo.
Placebo
Administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY4292009
Administered orally
Placebo
Administered orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If male, meets one of the following:
* can procreate and agree to use one of the accepted to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration.
* is unable to procreate; defined as surgically sterile (i.e., has undergone a vasectomy at least 180 days prior to the first study drug administration)
* if female, meets one of the following:
* is of childbearing potential and agrees to use an acceptable contraceptive method.
* is of non-childbearing potential, defined as either:
* Surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or
* is in a postmenopausal state:
* At least 1 year without menses and without an alternative medical condition prior to the screening, and follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at screening or at least 1 year without menses and without an alternative medical condition prior to the screening, follicle stimulating hormone FSH levels \< 40 milli-international units per milliliter (mIU/mL) and estradiol serum level ≤150 picomole/Liter (pmol/L) at screening
Exclusion Criteria
* Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum, chewing tobacco, electronic cigarettes) within 1 month before screening and/or inability to refrain from nicotine from screening until the end of the study
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altasciences Company Inc.
Mount Royal, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Morf-440-101
Identifier Type: OTHER
Identifier Source: secondary_id
J6O-MC-UMAA
Identifier Type: OTHER
Identifier Source: secondary_id
27728
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.